A Phase 3 interventional study of MabThera/Rituxan and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 115 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-10-25.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 5th largest by enrollment, is one of 2 that started in 2003, is one of 27 in phase 3, and was the 14th registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 27 · Phase 4 14
First in 2001; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 520 is above the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 159 across the 63 interventional studies. Of the 57 that completed or were terminated, 37 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 63 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 24th largest by enrollment of the 141 interventional ones that give a count, is one of 3 that started in 2003, is one of 85 in phase 3, and was the 32nd registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of rituximab combined with MTX in participants with active rheumatoid arthritis (RA) who have had an inadequate response to anti-Tumor Necrosis (TNF) alpha therapy. The anticipated time in the study is up to 2 years and the target sample size is 500 participants. Eligible participants may receive re-treatment with rituximab under a separate protocol WA17531.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg per os (p.o.) or parenterally once a week up to 24 weeks and will be followed up to Week 104.
Drug: Methotrexate · Other: Placebo
Participants will be administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and will be followed up to Week 104.
Drug: MabThera/Rituxan · Drug: Methotrexate
Drug page: Rituximab
1
2
3
Number of Participants With American College of Rheumatology 20 Response at Week 24
American College of Rheumatology (ACR) 20 response is defined as \>= 20% improvement (reduction) in score compared with baseline for both tender joint count (TJC)-68 joints and swollen joint count (SJC)-66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours using a Visual Analog Scale (VAS) ranging from score 0 (no pain) to 100 (unbearable pain); Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging score 0 (no disease activity) to 100 (maximum disease activity); Health Assessment Questionnaire (HAQ):8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do) for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR).
Time frame: Week 24
Number of Participants With an ACR 50 Response at Week 24
ACR 50 response is defined as a \>= 50% improvement (reduction) in score compared with baseline for both TJC -68 joints and SJC -66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a VAS ranging from score '0'=no pain to score '100'=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging from score '0'=no disease activity to score '100'=maximum disease activity; HAQ : Health Assessment Questionnaire (HAQ):which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either CRP or ESR.
Time frame: Week 24
Number of Participants With ACR 70 Response at Week 24
ACR 70 response is defined as a \>= 70% improvement (reduction) in score compared with baseline for both TJC -68 joints and SJC -66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a VAS ranging from score '0'=no pain to score '100'=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging from score '0'=no disease activity to score '100'=maximum disease activity; HAQ : Health Assessment Questionnaire (HAQ):which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either CRP or ESR.
Time frame: Week 24
Mean Change From Baseline in Disease Activity Score of 28 Joints at Week 24
The disease activity score (DAS28) is an evaluation index of rheumatoid arthritis. The DAS28 applies a mathematical formula based on the following parameters: 1. TJC-28 joints, 2. SJC -28 joints, 3. ESR or CRP measurement, 4. Participant's judgement on his own overall health (global health \[GH\]) status expressed by a VAS (0 \[no disease activity\] to 100 \[maximum disease activity\]). The mathematical formula is 0.56 × √28TJC + 0.28 × √28SJC + 0.7 x loge ESR + 0.014 × GH. The DAS28 scale ranges from score of 0 to 10, where lower scores indicate best disease control and higher scores indicate worsening of disease. Change from Baseline = difference between the score at Week 24 and the score at Baseline.
Time frame: From Baseline (Day 1) to Week 24
Percentage of Participants With DAS28 Low Disease Activity and DAS28 Remission at Week 24
The DAS28 is an evaluation index of RA. The DAS28 applies a mathematical formula based on the following parameters: 1. TJC- 28 joints, 2. SJC- 28 joints, 3. ESR or CRP measurement, 4. Participant's judgement on his own overall health status (GH) expressed by a visual analogue scale VAS (0 \[no disease activity\] to 100 \[maximum disease activity\]). The mathematical formula is 0.56 × √28TJC + 0.28 × √28SJC + 0.7 x loge ESR + 0.014 × GH. The DAS28 scale ranges from score of 0 to 10. A participant was categorized as having low disease activity, if participant's DAS28 score was \<= 3.2, and was categorized as having clinical remission if participant's DAS28 score was \< 2.6.
Time frame: Week 24
Number of Participants With Good, Moderate, or no European League Against Rheumatism Responses at Week 24
European League Against Rheumatism (EULAR) response is defined based on the DAS28 score and the EULAR response criteria (Van Gestel et al, 1996 and 1999). The DAS28 scale ranges from score of 0 to 10, where lower scores indicate best disease control and higher scores indicate worsening of disease. At a given visit, participants with a DAS28 score of \< 3.2 are considered good responders if the change from baseline in their DAS28 score is \>1.2. Participants with a DAS28 score \>= 3.2 to 5.1 are considered moderate responders if the change from baseline in their DAS28 score is \<=1.2 to \>=0.6. Participants with DAS28 score \>5.1 are considered non-responders if the change from baseline in their DAS28 score is \<=1.2 to \>=0.6.
Time frame: Week 24
Percentage Change From Baseline in the ACR Core Set (SJC, TJC, Patient's and Physician's Global Assessments, Health Assessment Questionnaire, Pain, C-Reactive Protein, and Erythrocyte Sedimentation Rate) Score
Percentage change in the scores of the following parameters of ACR core set relative to respective baseline scores in both study arms was analyzed : SJC (28 and 66 joints) and TJC (28 and 66 joints), patient's global assessment and physician's global assessment based on disease activity (both are expressed by VAS \[0 = no disease activity to 100 = maximum disease activity\]), HAQ (based on HAQ disability index \[HAQDI\]) which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst), pain assessment using a VAS ranging from score 0 (no pain) to 100 (unbearable pain), CRP concentration, and ESR.
Time frame: From Baseline (Day 1) to Week 24
Mean Change From Baseline of Short Form 36 Total Scores at Week 24
The Short Form (SF)-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Transforming and standardizing these domains leads to the calculation of the physical component summary and mental component summary measures. Scores on each item were summed and averaged (range 0 \[worst\] to 100 \[best\]); increase in score from baseline indicated improvement. Change from Baseline = difference between the score at Week 24 and the score at Baseline.
Time frame: From Baseline (Day 1) to Week 24
Number of Participants With Categorical Change From Baseline in the Physical Component Scores of SF-36
The SF-36 determined participants' overall quality of life by assessing :1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Scores on physical component were summed and averaged (range 0 \[worst\] to 100 \[best\]); If participants' had shown change from baseline in physical health component score \>5.42, it was considered as improved; score between -5.42 to 5.42 was considered as unchanged, and score \< -5.42 was considered as worsened. Change from Baseline = difference between the score of physical component at Week 24 and the score at Baseline.
Time frame: From Baseline (Day 1) to Week 24
Number of Participants With Change From Baseline in the Mental Component Scores of SF-36
The SF-36 determined participants' overall quality of life by assessing :1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Scores on mental component were summed and averaged (range = 0 \[worst\]-100 \[best\]); increase from baseline indicated improvement. If participants' had shown change from baseline in mental health score \>6.33, it was considered as improved; scores between -6.33 to 6.33 was considered unchanged, and score \<-6.33 was considered as worsened. Change from Baseline = difference between the mental component score at Week 24 and the score at Baseline.
Time frame: From Baseline (Day 1) to Week 24
Mean Change From Baseline in the Genant-modified Sharp Joint Space Narrowing Score, Genant-modified Sharp Total Score, and Erosion Score
The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290. For all the three radiograph assessment, the minimum score is 0. A higher score indicates more damage and a negative change score indicates improvement. The change in score is to be calculated as: Change from Baseline = difference between the score at Weeks 24, 56, or 104 and the score at Baseline.
Time frame: From Baseline (Day 1) to Weeks (W) 24, 56, and 104
Percentage of Participants Without Erosive Progression
The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140 which is normalized to 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage and negative change score indicates improvement.
Time frame: Up to Week 104
A total of 520 participants were enrolled in the study conducted from 02 May 2003 and 12 July 2012 in 11 countries.
| Milestone | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| Started | 208 | 308 |
| Completed | 111 | 253 |
| Not completed | 97 | 55 |
| Withdrew: Lack of efficacy | 83 | 37 |
| Withdrew: Refused treatment | 5 | 5 |
| Withdrew: Adverse event | 1 | 8 |
| Withdrew: Failure to return | 3 | 4 |
| Withdrew: Rescue therapy | 2 | 0 |
| Withdrew: Incorrect diagnosis and treatment | 0 | 1 |
| Withdrew: Due to clinical hold | 1 | 0 |
| Withdrew: Went onto rescue therapy | 1 | 0 |
| Withdrew: Participant unblinded (clinical hold) | 1 | 0 |
| Milestone | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| Started | 208 | 308 |
| Completed | 103 | 83 |
| Not completed | 105 | 225 |
| Withdrew: Adverse event | 2 | 5 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lack of efficacy | 3 | 12 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Refused treatment | 4 | 7 |
| Withdrew: Failure to return | 1 | 2 |
| Withdrew: Movement into re-treatment study | 77 | 183 |
| Withdrew: Other | 17 | 14 |
American College of Rheumatology (ACR) 20 response is defined as \>= 20% improvement (reduction) in score compared with baseline for both tender joint count (TJC)-68 joints and swollen joint count (SJC)-66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours using a Visual Analog Scale (VAS) ranging from score 0 (no pain) to 100 (unbearable pain); Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging score 0 (no disease activity) to 100 (maximum disease activity); Health Assessment Questionnaire (HAQ):8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do) for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR).
| participants | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| Number of Participants With American College of Rheumatology 20 Response at Week 24 | 36 | 153 |
ACR 50 response is defined as a \>= 50% improvement (reduction) in score compared with baseline for both TJC -68 joints and SJC -66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a VAS ranging from score '0'=no pain to score '100'=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging from score '0'=no disease activity to score '100'=maximum disease activity; HAQ : Health Assessment Questionnaire (HAQ):which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either CRP or ESR.
| participants | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| Number of Participants With an ACR 50 Response at Week 24 | 11 | 80 |
ACR 70 response is defined as a \>= 70% improvement (reduction) in score compared with baseline for both TJC -68 joints and SJC -66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a VAS ranging from score '0'=no pain to score '100'=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging from score '0'=no disease activity to score '100'=maximum disease activity; HAQ : Health Assessment Questionnaire (HAQ):which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either CRP or ESR.
| participants | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| Number of Participants With ACR 70 Response at Week 24 | 3 | 37 |
The disease activity score (DAS28) is an evaluation index of rheumatoid arthritis. The DAS28 applies a mathematical formula based on the following parameters: 1. TJC-28 joints, 2. SJC -28 joints, 3. ESR or CRP measurement, 4. Participant's judgement on his own overall health (global health \[GH\]) status expressed by a VAS (0 \[no disease activity\] to 100 \[maximum disease activity\]). The mathematical formula is 0.56 × √28TJC + 0.28 × √28SJC + 0.7 x loge ESR + 0.014 × GH. The DAS28 scale ranges from score of 0 to 10, where lower scores indicate best disease control and higher scores indicate worsening of disease. Change from Baseline = difference between the score at Week 24 and the score at Baseline.
| units on a scale | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| Mean Change From Baseline in Disease Activity Score of 28 Joints at Week 24 | -0.4 ± 1.17 | -1.9 ± 1.60 |
The DAS28 is an evaluation index of RA. The DAS28 applies a mathematical formula based on the following parameters: 1. TJC- 28 joints, 2. SJC- 28 joints, 3. ESR or CRP measurement, 4. Participant's judgement on his own overall health status (GH) expressed by a visual analogue scale VAS (0 \[no disease activity\] to 100 \[maximum disease activity\]). The mathematical formula is 0.56 × √28TJC + 0.28 × √28SJC + 0.7 x loge ESR + 0.014 × GH. The DAS28 scale ranges from score of 0 to 10. A participant was categorized as having low disease activity, if participant's DAS28 score was \<= 3.2, and was categorized as having clinical remission if participant's DAS28 score was \< 2.6.
| percentage of participants | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| Low disease activity | 2 | 15 |
| Remission | 0 | 9 |
European League Against Rheumatism (EULAR) response is defined based on the DAS28 score and the EULAR response criteria (Van Gestel et al, 1996 and 1999). The DAS28 scale ranges from score of 0 to 10, where lower scores indicate best disease control and higher scores indicate worsening of disease. At a given visit, participants with a DAS28 score of \< 3.2 are considered good responders if the change from baseline in their DAS28 score is \>1.2. Participants with a DAS28 score \>= 3.2 to 5.1 are considered moderate responders if the change from baseline in their DAS28 score is \<=1.2 to \>=0.6. Participants with DAS28 score \>5.1 are considered non-responders if the change from baseline in their DAS28 score is \<=1.2 to \>=0.6.
| participants | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| No response | 157 | 105 |
| Moderate response | 40 | 149 |
| Good response | 4 | 44 |
Percentage change in the scores of the following parameters of ACR core set relative to respective baseline scores in both study arms was analyzed : SJC (28 and 66 joints) and TJC (28 and 66 joints), patient's global assessment and physician's global assessment based on disease activity (both are expressed by VAS \[0 = no disease activity to 100 = maximum disease activity\]), HAQ (based on HAQ disability index \[HAQDI\]) which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst), pain assessment using a VAS ranging from score 0 (no pain) to 100 (unbearable pain), CRP concentration, and ESR.
| percent change | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| SJC (66) | -5.6 ± 59.19 | -43.0 ± 52.65 |
| SJC (28) | -7.1 ± 55.35 | -41.3 ± 52.77 |
| TJC (68) | 7.2 ± 144.58 | -41.8 ± 52.39 |
| TJC (28) | 15.7 ± 195.94 | -42.0 ± 63.47 |
| Physician's global assessment | -4.2 ± 47.23 | -40.8 ± 39.31 |
| Patient's global assessment | -3.1 ± 44.01 | -25.4 ± 117.90 |
| Patient's pain assessment | 2.8 ± 55.61 | -23.8 ± 131.59 |
| HAQ | -2.0 ± 30.46 | -24.3 ± 34.92 |
| CRP | 80.0 ± 452.94 | -36.3 ± 80.3 |
| ESR | 11.4 ± 95.95 | -29.3 ± 59.92 |
The Short Form (SF)-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Transforming and standardizing these domains leads to the calculation of the physical component summary and mental component summary measures. Scores on each item were summed and averaged (range 0 \[worst\] to 100 \[best\]); increase in score from baseline indicated improvement. Change from Baseline = difference between the score at Week 24 and the score at Baseline.
| units on a scale | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| Physical score | 0.9 ± 5.65 | 5.8 ± 8.47 |
| Mental health score | 1.3 ± 9.43 | 4.7 ± 11.75 |
The SF-36 determined participants' overall quality of life by assessing :1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Scores on physical component were summed and averaged (range 0 \[worst\] to 100 \[best\]); If participants' had shown change from baseline in physical health component score \>5.42, it was considered as improved; score between -5.42 to 5.42 was considered as unchanged, and score \< -5.42 was considered as worsened. Change from Baseline = difference between the score of physical component at Week 24 and the score at Baseline.
| participants | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| Improved | 25 | 141 |
| Unchanged | 158 | 136 |
| Worsened | 14 | 17 |
The SF-36 determined participants' overall quality of life by assessing :1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Scores on mental component were summed and averaged (range = 0 \[worst\]-100 \[best\]); increase from baseline indicated improvement. If participants' had shown change from baseline in mental health score \>6.33, it was considered as improved; scores between -6.33 to 6.33 was considered unchanged, and score \<-6.33 was considered as worsened. Change from Baseline = difference between the mental component score at Week 24 and the score at Baseline.
| participants | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| Improved | 40 | 111 |
| Unchanged | 128 | 144 |
| Worsened | 29 | 39 |
The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290. For all the three radiograph assessment, the minimum score is 0. A higher score indicates more damage and a negative change score indicates improvement. The change in score is to be calculated as: Change from Baseline = difference between the score at Weeks 24, 56, or 104 and the score at Baseline.
| units on a scale | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| Sharp-Genant total score, W24, n = 201, 298 | -4.3 ± 24.09 | -1.2 ± 20.90 |
| Sharp-Genant total score, W56, n = 184, 273 | 2.31 ± 5.283 | 1.00 ± 2.751 |
| Sharp-Genant total score, W104, n = 186,279 | 2.82 ± 6.398 | 1.16 ± 3.429 |
| Erosion score, W24, n = 201, 298 | -1.6 ± 12.15 | -0.4 ± 10.45 |
| Erosion score, W56, n = 184, 273 | 1.32 ± 3.155 | 0.59 ± 1.843 |
| Erosion score, W104, n = 186,279 | 1.81 ± 4.187 | 0.73 ± 2.262 |
| Joint space narrowing score, W24, n = 201, 298 | -2.5 ± 12.71 | -0.9 ± 10.90 |
| Joint space narrowing score, W56, n = 184, 273 | 0.99 ± 2.571 | 0.41 ± 1.323 |
| Joint space narrowing score, W104, n = 186,279 | 1.01 ± 2.618 | 0.43 ± 1.563 |
The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140 which is normalized to 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage and negative change score indicates improvement.
| percentage of participants | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| Baseline to Year 1, n = 186, 278 | 51 | 66 |
| Year 1 to Year 2, n = 186, 278 | 58 | 73 |
| Baseline to Year 2, n = 187, 281 | 44 | 60 |
Collected over Up to Week 104. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Plus Methotrexate | — | 26/208 (12.5%) | 152/208 (73.1%) |
| Rituximab Plus Methotrexate | — | 50/308 (16.2%) | 225/308 (73.1%) |
| Event | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 5/208 | 6/308 |
| PneumoniaInfections and infestations | 0/208 | 3/308 |
| Myocardial infarctionCardiac disorders | 1/208 | 3/308 |
| Deep vein thrombosisVascular disorders | 1/208 | 3/308 |
| HypertensionVascular disorders | 1/208 | 3/308 |
| FallInjury, poisoning and procedural complications | 2/208 | 0/308 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/208 | 2/308 |
| CellulitisInfections and infestations | 0/208 | 2/308 |
| DiverticulitisInfections and infestations | 0/208 | 2/308 |
| Escherichia urinary tract infectionInfections and infestations | 0/208 | 2/308 |
| Event | Placebo Plus Methotrexate | Rituximab Plus Methotrexate |
|---|---|---|
| Rheumatoid ArthritisMusculoskeletal and connective tissue disorders | 87/208 | 106/308 |
| Upper Respiratory Tract infectionInfections and infestations | 17/208 | 36/308 |
| HeadacheNervous system disorders | 21/208 | 31/308 |
| NasopharyngitisInfections and infestations | 15/208 | 30/308 |
| DiarrhoeaGastrointestinal disorders | 18/208 | 21/308 |
| HypertensionVascular disorders | 12/208 | 26/308 |
| BronchitisInfections and infestations | 15/208 | 25/308 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/208 | 24/308 |
| NauseaGastrointestinal disorders | 8/208 | 23/308 |
| Urinary Tract InfectionInfections and infestations | 15/208 | 21/308 |
Safety population included participants who were randomized and received any part of an infusion of the study drug.
| Age, Continuous(years) | Placebo Plus Methotrexate | Rituximab Plus Methotrexate | Total |
|---|---|---|---|
| Median | 55.0 (20 to 79) | 53.0 (20 to 81) | 53.0 (20 to 81) |
| Sex: Female, Male(Participants) | Placebo Plus Methotrexate | Rituximab Plus Methotrexate | Total |
|---|---|---|---|
| Female | 168 | 251 | 419 |
| Male | 40 | 57 | 97 |
Showing the first 100 of 115 sites across 11 countries. Choose a country and city above to see the rest.
The record gives a start of May 2003, a primary completion of Jan 2005 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 11 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab